187 related articles for article (PubMed ID: 35459193)
1. RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers.
Xia L; Tian E; Yu M; Liu C; Shen L; Huang Y; Wu Z; Tian J; Yu K; Wang Y; Xie Q; Zhu D
J Exp Clin Cancer Res; 2022 Apr; 41(1):155. PubMed ID: 35459193
[TBL] [Abstract][Full Text] [Related]
2. RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer.
Tian EM; Yu MC; Feng M; Lu LX; Liu CL; Shen LA; Wang YH; Xie Q; Zhu D
Pharmacol Res; 2021 Oct; 172():105793. PubMed ID: 34339836
[TBL] [Abstract][Full Text] [Related]
3. Targeting KDM4C enhances CD8
Jie X; Chen Y; Zhao Y; Yang X; Xu Y; Wang J; Meng R; Zhang S; Dong X; Zhang T; Yang K; Xu S; Wu G
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121645
[TBL] [Abstract][Full Text] [Related]
4. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Biaryl Amide Derivatives as Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.
Lu L; Huang Y; Song M; Sun N; Xia L; Yu M; Zhao M; Qiu R; Chen JA; Zhao Y; Wang H; Guo H; Li Y; Zhu D; Wang Y; Xie Q
J Med Chem; 2023 Dec; 66(23):16091-16108. PubMed ID: 37982494
[TBL] [Abstract][Full Text] [Related]
6. CXCL10 mediates CD8
Yan W; Qiu L; Yang M; Xu A; Ma M; Yuan Q; Ma X; Liang W; Li X; Lu Y
Cancer Lett; 2023 Jul; 567():216263. PubMed ID: 37354983
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
8. Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Agonists as Potential Small Molecule Therapeutics for Cancer Immunotherapy.
Qiu R; Wang Y
J Med Chem; 2018 Jul; 61(14):5794-5804. PubMed ID: 29412659
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel N-sulfonamide-tetrahydroisoquinolines as potent retinoic acid receptor-related orphan receptor γt agonists.
Ma X; Sun N; Li X; Fu W
Eur J Med Chem; 2021 Oct; 222():113585. PubMed ID: 34118722
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor RUNX3 promotes CD8
Song Q; Shang J; Zhang C; Chen J; Zhang L; Wu X
J Cell Biochem; 2020 Jun; 121(5-6):3208-3220. PubMed ID: 31898342
[TBL] [Abstract][Full Text] [Related]
11. CD8+ T Cells That Coexpress RORγt and T-bet Are Functionally Impaired and Expand in Patients with Distal Bile Duct Cancer.
Chellappa S; Hugenschmidt H; Hagness M; Subramani S; Melum E; Line PD; Labori KJ; Wiedswang G; Taskén K; Aandahl EM
J Immunol; 2017 Feb; 198(4):1729-1739. PubMed ID: 28053236
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
14. Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Lucarini V; Melaiu O; D'Amico S; Pastorino F; Tempora P; Scarsella M; Pezzullo M; De Ninno A; D'Oria V; Cilli M; Emionite L; Infante P; Di Marcotullio L; De Ioris MA; Barillari G; Alaggio R; Businaro L; Ponzoni M; Locatelli F; Fruci D
J Exp Clin Cancer Res; 2022 Nov; 41(1):326. PubMed ID: 36397148
[TBL] [Abstract][Full Text] [Related]
15. Ursolic acid inhibits Th17 cell differentiation via STAT3/RORγt pathway and suppresses Schwann cell-mediated Th17 cell migration by reducing CXCL9/10 expression.
Xu H; Yu AL; Zhao DP; Meng GY; Wang L; Shan M; Hu NX; Liu YL
Innate Immun; 2022 Jul; 28(5):155-163. PubMed ID: 35548957
[TBL] [Abstract][Full Text] [Related]
16. The RORγt-CCR6-CCL20 axis augments Th17 cells invasion into the synovia of rheumatoid arthritis patients.
Kaneko S; Kondo Y; Yokosawa M; Furuyama K; Segawa S; Tsuboi H; Kanamori A; Matsumoto I; Yamazaki M; Sumida T
Mod Rheumatol; 2018 Sep; 28(5):814-825. PubMed ID: 29251019
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
18. Discovery of tert-amine-based RORγt agonists.
Qiu R; Yu M; Gong J; Tian J; Huang Y; Wang Y; Xie Q
Eur J Med Chem; 2021 Nov; 224():113704. PubMed ID: 34303081
[TBL] [Abstract][Full Text] [Related]
19. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
Reschke R; Yu J; Flood B; Higgs EF; Hatogai K; Gajewski TF
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593622
[TBL] [Abstract][Full Text] [Related]
20. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
